{"id":"NCT04950127","sponsor":"GlaxoSmithKline","briefTitle":"Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)","officialTitle":"A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-08-27","primaryCompletion":"2024-10-28","completion":"2024-12-20","firstPosted":"2021-07-06","resultsPosted":"2025-07-22","lastUpdate":"2025-07-22"},"enrollment":238,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pruritus"],"interventions":[{"type":"DRUG","name":"Linerixibat","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Part A: Linerixibat 40 milligrams (mg)","type":"EXPERIMENTAL"},{"label":"Part A: Placebo","type":"EXPERIMENTAL"},{"label":"Part B: Placebo in Part A and Part B","type":"PLACEBO_COMPARATOR"},{"label":"Part B: Placebo in Part A and Linerixibat 40 mg in Part B","type":"EXPERIMENTAL"},{"label":"Part B: Linerixibat 40 mg in Part A and Placebo in Part B","type":"EXPERIMENTAL"},{"label":"Part B: Linerixibat 40 mg in Part A and Part B","type":"EXPERIMENTAL"}],"summary":"This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.","primaryOutcome":{"measure":"Part A: Mean Change From Baseline in Monthly Itch Scores Over 24 Weeks Using Numerical Rating Scale (NRS)","timeFrame":"Baseline and up to Week 24","effectByArm":[{"arm":"Part A: Linerixibat 40 Milligrams (mg)","deltaMin":-2.86,"sd":null},{"arm":"Part A: Placebo","deltaMin":-2.15,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":114,"countries":["United States","Argentina","Belgium","Brazil","Bulgaria","Canada","China","Czechia","France","Germany","Greece","Israel","Italy","Japan","Mexico","Poland","Russia","Spain","United Kingdom"]},"refs":{"pmids":["37953500"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":118},"commonTop":["Diarrhoea","Abdominal pain","Nausea","Constipation","Alanine aminotransferase increased"]}}